Discontinue of if serious skin reactions are suspected. Not recommended for the treatment of asymptomatic hyperuricemia. CV death. Increase in gout flares after initiation. Measure LFT promptly in patients who report symptoms that may indicate liver injury, including fatigue, anorexia, right upper abdominal discomfort, dark urine or jaundice. Not recommended in patients whom the rate of urate formation is greatly increased (eg, malignant disease, Lesch-Nyhan syndrome). Caution before driving, using machinery or participating in dangerous activities. Caution when administering to breastfeeding women.